Angeliq
NDC 54868-6184
Product Information
Angeliq is a NDA-approved product labeled by Physicians Total Care, Inc.. This medication is used to reduce menopause symptoms. It is supplied as a pink product. This product entry covers the primary NDC 54868-6184 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
CK
Code Structure Chart
Product Details
What is NDC 54868-6184?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- ESTRADIOL (UNII: 4TI98Z838E)
- ESTRADIOL (UNII: 4TI98Z838E) (Active Moiety)
- DROSPIRENONE (UNII: N295J34A25)
- DROSPIRENONE (UNII: N295J34A25) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- STARCH, CORN (UNII: O8232NY3SJ)
- FERRIC OXIDE RED (UNII: 1K09F3G675)
- HYPROMELLOSES (UNII: 3NXW29V3WO)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- MODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE) (UNII: 461P5CJN6T)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- POVIDONE K25 (UNII: K0KQV10C35)
- TALC (UNII: 7SEV7J4R1U)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1483552 - drospirenone 0.5 MG / estradiol 1 MG Oral Tablet
- RxCUI: 1483553 - {28 (drospirenone 0.5 MG / estradiol 1 MG Oral Tablet) } Pack
- RxCUI: 1483553 - Drospiren-Eth estra 0.5-1 MG (28) Oral Tablet 28 Day Pack
- RxCUI: 1483553 - drospirenone 0.5 MG / Ethinyl Estradiol 1 MG 28 Oral Tablet Pack
- RxCUI: 1483554 - {28 (drospirenone 0.5 MG / estradiol 1 MG Oral Tablet) } Pack [Angeliq 0.5/1 28 Day]
* Please review the full disclaimer at the bottom of this page.